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Introduction  
Drug shortage in the United States is defined as "a situation in 
which the total supply of all clinically interchangeable 
versions of an FDA-regulated drug is inadequate to meet the 
current or projected demand at the user level".
1  A term 
rarely encountered decades ago, it was not until recent years 
that the magnitude and impact of drug shortage progressed 
to critical levels. While the annual new drug shortages list 
remained fairly stable prior to 2005, a rapid, steady increase 
has been observed over the second half of the past decade. 
In 2010, there were 211 newly reported drug shortages, 
tripling the amount in 2006 (Figure 1), with almost 75% being 
sterile injectables.
2 The shortage is present in all healthcare 
practice settings and affects nearly all drug classes, with 
critical therapeutic areas such as oncology and antimicrobials 
being affected the most.
3 As of October 2011, 232 shortages 
have been reported from multiple resources, exceeding the 
records in 2010, and it is estimated that 360 products will be 
in shortage by the end of 2011.
4, 5, 6, 7 
 
In October 2011, President Obama signed an executive order 
guiding the Food and Drug Administration (FDA) to set up 
efforts to relieve shortages.
7 The latest White House initiative 
that does not require congressional approval, the order 
directs the FDA to enforce reporting obligations for 
manufacturers on impending drug withdrawls, expedites 
review progress of new prescription drugs and forges 
collaboration with the Justice Department to prosecute price 
gouging from the gray market. However, these approaches 
do not directly tackle the fundamental causes of drug 
shortages, and the initiative is unlikely to have an immediate 
impact on the situation.
8  
 
Causes of Drug Shortages 
The causes of drug shortages are complicated and rooted in 
every phase of  a drug’s life cycle. Yet to be systematically 
studied, many trends contribute to the shortage, comprising 
shortage of raw materials, issues related to manufacturers 
(pharmaceutical mergers and acquisitions, decisions based on 
projected profit), regulatory and legislative factors, and labor 
disruption. It is worth noting that approximately 27% of the 
shortages are unexplained.
9  
 
1. Unavailability of Raw Materials  
Suboptimal quality of raw materials may have a profound 
impact on drug shortages. Raw material shortage can result 
from a number of factors, including a sole source 
manufacturer that ceases operation, suboptimal quality of 
the raw material, and wars that disrupts importation. In 2010, 
nearly half of drug shortages resulted from quality issues of 
raw materials, including impurities, microbial contamination, 
and chemical instability.
3 Currently, eighty percent of the raw 
materials come from foreign markets, which imposes 
challenges to quality control of the raw materials.
10 For 
example, the market for Chinese active pharmaceutical 
ingredients (APIs) was reduced by nearly 50% in 2010, partly 
attributable to concerns over quality issues with Chinese APIs, 
exemplified by heparin contamination in 2008.
11 The 
shortages can be especially problematic when a major or 
sole-source supplier ceases production of raw materials, 
affecting all of the producers of finished product.
12  
 
2. Manufacturer Decisions, Merger, and Acquisition  
A number of factors can lead to manufacturer's decision to 
discontinue the production of certain drugs. These may 
include: discontinuing API due to investments required for 
new quality requirements imposed by FDA, diminishing 
demand, negligible profitability, for liability reasons, to utilize 
resources elsewhere, etc. For example, GlaxoSmithKline 
pulled its Lymerix vaccine off the market due to diminishing 
demand and increasing consumer criticism.
13 Nearly 20% of 
injectable drug shortages were consequences of product 
discontinuations. Unfortunately, manufacturers are not 
obligated to inform FDA about product discontinuation plans 
unless their product is the only medication to treat a life-
threatening condition or debilitating disease. In addition, 
there is no legal requirement for a firm to continue producing 
any drug, even one that is deemed medically necessary.
3 
Consolidations and mergers among manufacturers can result 
in decisions to consolidate product lines or decisions to 
discontinue the manufacture of certain drugs, particularly if 
companies have two similar products.  
 
3. Regulatory Issues, Noncompliance with Current Good 
Manufacturing Practices (cGMPs) 
Another significant contributor to drug shortages results from 
regulatory barriers and ambiguities, including lack of 
sufficient communications between FDA and manufacturers. 
Specific cases include a lengthy period for FDA review of 
Abbreviated New Drug Applications (ANDAs) and 
supplemental applications, which are necessary steps for a 
change in source for API and change in manufacturer. Some 
manufacturers view the process of completing a New Drug Idea Paper  POLICY 
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Application (NDA) to be costly, lengthy and complicated, and 
this has been a disincentive for entering a market. 
 
The FDA requires manufacturers to comply with the Good 
Manufacturing Practices (cGMP) Act. Although the cGMP 
requirements were established to be flexible in order to allow 
each manufacturer to use individualized approaches, the 
cGMP change over time. The shortage of immune globulin 
intravenous pentelate, an injectable drug for enhancing the 
immune system, resulted from a manufacturer's failure to 
meet regulatory standards. Manufacturers that are in 
compliance and produce the same drug tend to operate close 
to  their production capacity, and they may be unable to 
meet greater demand.
14 They plan to produce the quantity 
they expect to sell. 
 
4. Unexpected Demand  
An outbreak of a rare disease can quickly disrupt the regular 
supply chain. In 2009, when the H1N1 pandemic came on the 
scene, FDA amended the original Emergency Use 
Authorizations (EUAs) for both Tamiflu and Relenza as part of 
the federal government's responses to the public health 
emergency.
15 Subsequently, the shortages of Tamiflu were 
reported everywhere, particularly in pediatric practices.
16  
 
5. Natural Disasters  
Natural disasters may result in a shortage by affecting the 
raw materials needed by the sole producer of a drug and 
impose unexpected impairment to manufacturing facilities. 
Hurricane George (1998) caused major damage in Puerto 
Rico. As a consequence, several drug shortages occurred as 
the many pharmaceutical manufacturing facilities on the 
island were severely disrupted.
14  
 
6. Labor Disruptions  
Labor disruptions attribute to drug shortages by diminishing 
the productivity of the manufacturing sector.  
 
Other causes include voluntary recalls from manufacturers, 
changes in clinical practice patterns, and restricted 
distribution. The above reasons are not mutually exclusive 
and in many cases, shortages may result from a combination 
of factors. The above possibilities may be aggravated by a 
number of factors. If a drug is a sole product in a therapeutic 
area, then any dislocation in supply can result in unavailability 
of the drug. However, even if the drug is not a sole source, 
but manufactured by a small number of companies a 
decrease in supply by one manufacturer can lead to 
shortages if the other manufacturers are unable to increase 
production to compensate for the shortfall.  
 
 
Consequences of Drug Shortages  
1. Impact of Drug Shortages on Healthcare Quality  
According to the report by the Drug Information Services of 
the University of Utah, the five drug classes in 2010 that 
encountered the most drug shortages were CNS (28 
shortages, mainly anesthesiology), antineoplastics (20 
shortages), antimicrobials (19 shortages), electrolytes (17 
shortages), cardiovascular (17 shortages) and autonomic (13 
shortages).
17 These products are essential for treating most 
critical health conditions and shortages in any of them 
inevitably caused disruptions in patient safety and quality of 
health care.  
 
In situations where a drug in shortage is the sole treatment 
option for a life-threatening condition or appropriate 
alternative agents are difficult to obtain, patients' lives can be 
immediately placed at risk. Incidences of shortage-related 
patient deaths have been reported in all healthcare practice 
settings in the past 15 months and at least 15 deaths have 
been attributed to the shortages.
18 Even when alternative 
drugs are available, prescription errors due to unfamiliarity 
with the new regimen, adverse events caused by unexpected 
drug-drug interactions and suboptimal treatment outcomes 
associated with alternative agents can place severe distress 
to healthcare practices. For example, prochlorperazine was 
used in combination with droperidol to treat Chemotherapy 
Induced Nausea and Vomiting (CINV). After the shortage of 
prochlorperazine occurred at the University of Pittsburgh 
Medical Center, promethazine was selected for therapeutic 
interchange. The adverse events related to the use of 
promethazine had increased by over 3.3 fold in the 
subsequent year, due to unexpected drug-drug interactions.
19 
A national survey conducted last year among 1,800 
healthcare practitioners revealed that 80% of the participants 
expressed difficulty in obtaining a suitable alternative 
medication and 64% encountered risk of related adverse 
events.
20 In June 2011, the shortage of paclitaxel, the generic 
version of Taxol, has threatened lives and may have 
shortened survival of cancer patients, due to the lack of 
equally effective substitutes.
21 Shortages of drugs for 
attention deficit hyperactivity disorder (ADHD) led consumers 
to seek pricey alternatives that are less effective.
22 According 
to a recent report, drug shortage has also caused a barrier for 
patient enrollment in clinical trials. More than 300 NIH-
funded clinical trials involve a drug that is in shortage.
23  
 
2. Financial Impact of Drug Shortages  
The results of drug shortage, particularly the rapid increase in 
its magnitude, have imposed substantial financial burdens on 
hospitals and to the healthcare system as a whole. To 
respond to shortages, health care organizations have taken 
various approaches, which can divert resources away from Idea Paper  POLICY 
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routine care. According to a survey conducted by Premier, a 
hospital buying group,  the annual financial impact of drug 
shortages on Premier alliance members alone exceeds $78 
million. More than $66 million (or 85 percent) of the impact is 
felt by Premier’s 2,500 hospital members, with the remaining 
amount within Premier’s non-acute care sites.
3 
  
3. Gray Market Distributors  
The gray market, also known as a parallel market, is a trade of 
products through supply channels which, while legal, is 
unintended, unofficial, unauthorized by the original 
manufacturer. Gray market distributors buy available drug 
supplies and sell them to providers or end purchasers at 
markups of several hundred percent. During times of drug 
shortages, this supply chain diversion may threaten drug 
integrity in addition to fleecing payers. According to a recent 
investigation led by Congressman Elijah Cummings
24, in the 
event of shortage for some critically needed medications, 
gray market vendors can raise the product price by more than 
80 times a typical contract price. For example, Cytarabine, a 
chemotherapy agent used to treat Acute Myeloid Leukemia 
(AML) and non-Hodgkin Lymphoma (NHL) in children and 
adults, was typically priced at approximately $12 per vial but 
was sold at over $900 per vial by a distributor from Southern 
Florida. The activities from gray market distributors have 
been wide-spread and aggressive. In July and August this 
year, the Institute for Safe Medication Practices (ISMP) 
conducted a survey regarding gray market activities and drug 
shortages which included healthcare providers from 549 
hospitals across the nation. Over half (56%) of all participants 
reported receiving daily solicitations from vendors offering 
pharmaceutical products no longer available through 
authorized channels. It is also suggested by more than 10% of 
respondents that gray market vendors may have also 
purchased vital medications with impending shortages from 
hospitals, presumably to sell to other healthcare providers at 
inflated prices.
25 Further investigations revealed deeper 
rooted issues in the multilayered nature in the gray market. 
Many distributors reported buying the medications at already 
highly inflated prices and selling them at a normally increased 
rate, thus they considered generated profits to be 
"reasonable".
26 
 
Reponses from Government, Health Care Organizations, and 
Pharmaceutical Markets   
1. FDA's Drug Shortage Program (DSP) 
Currently, FDA has limited regulatory authority in the battle 
against drug shortages. Established in 1999, under the Center 
for Drug Evaluation and Research (CDER), one of the FDA's 
five centers, the DSP is aimed at resolving all issues related to 
shortages of the products reviewed by the CDER and release 
information about these drugs to the public. The DSP 
primarily uses tools of communication, facilitation, and 
negotiation to formulate and implement effective plans for 
preventing and managing drug shortages.
28 
 
DSP maintains a partnership with the American Society of 
Health-System Pharmacists (ASHP), with the latter regularly 
sharing available data with the DSP. The DSP assesses the 
severity and duration of the shortage, as well as determines if 
the drug is medically necessary, currently defined as "…any 
drug used to treat or prevent a serious disease for which no 
appropriate substitute is adequately available".
27 A shortage 
involving medically necessary products is likely to cause 
significant disruption in patient care. FDA has established a 
website for posting information related to shortages of 
medically necessary products.
28 In addition to posting news 
on the webpage, the DSP staff answers each e-mail inquiry 
that it receives at its Drug Shortage email account.  
 
When shortages of medically necessary products occur, the 
DSP determines the cause and works with manufacturers and 
appropriate FDA components to develop short-term and 
long-term management plans.  
 
2. The American Society of Health-System Pharmacists (ASHP) 
In November 2010, a Drug Shortage Summit was held jointly 
by the ASHP, the American Society of Anesthesiologists, 
American Society of Clinical Oncology, and Institute for Safe 
Medication Practices (ISMP).
29 Participants included 
pharmaceutical manufacturers, wholesalers and distributors, 
the FDA, the University of Utah Drug Information Services, 
Premier and others. The goals were to: 1) Discuss the causes 
of drug shortages; 2) Examine the impact of drug shortage on 
healthcare quality; 3) Identify the need and feasibility for 
changes in public policy to relieve and eradicate the 
detrimental impact of drug shortage; 4) Develop an action 
plan based on the recommendations of stakeholders.  
 
Summit participants provided extensive recommendations to 
minimize the impact of drug shortages, including improving 
communication among stakeholders in the pharmaceutical 
supply chain and health care providers, and removing barriers 
faced by the FDA and drug manufacturers. With regard to 
handling regulatory and legislative factors that contributed to 
the shortage of drugs, it was recommended that greater 
authority should be given to FDA for requiring manufacturer 
advance notification of impending market withdrawals. 
Participants also proposed a revision of FDA's current 
definition of medically necessary.  
The FDA will facilitate their communications with 
manufacturers to relieve shortages with the hope to mitigate 
patient risk. Furthermore, an approval process for alternative Idea Paper  POLICY 
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products is subject to acceleration, based on reviewing the 
potential impact on healthcare quality and patient safety.
29  
 
3. The Preserving Access to Life-Saving Medications Act 
In February 2011, Senator Amy Klobuchar introduced a bill, S. 
296, the Preserving Access to Life-Saving Medications Act, 
that would provide FDA with key strategies to prevent drug 
shortages. These approaches include imposing a minimum of 
6 months in advance for manufacturers to report to FDA of an 
impending market exit or product discontinuation. The 
legislation also requires FDA to perform expedited re-
inspections of manufacturers in the case of a drug shortage.
30 
The bill granted the FDA authority to impose penalties on 
noncompliant manufacturers.  
 
Proposed Actions  
1. Strengthen FDA's roles  
Currently, FDA has limited authority in forecasting, 
preventing, and controlling drug shortages. The Drug 
Shortage Program (DSP), under Drug Evaluation and Research 
(CDER), one of the five centers within the FDA, receives 
information about drug shortages mainly from the public      
e-mail account maintained by DSP.
31 Report of shortages to 
the FDA is not an obligation of manufacturers, except for 
medically necessary products.
32 Furthermore, FDA is not 
granted authority to regulate product discontinuation, a 
decision usually made by manufacturers. Senator Klobuchar’s 
bill, S. 296, would require all pharmaceutical manufacturers 
to report to FDA at least 6 months before planned market 
exit.
33 The legislation also would provide feasibility for FDA to 
know the reasons for such discontinuations (e.g. whether it is 
caused by raw material shortage or lack of projected profits) 
and work with manufacturers to establish a continuity of 
operations plan to address drug shortages. While a 6-month 
period would leave considerable leeway for FDA to seek 
alternative solutions, a prolonged length should be 
recommended to accommodate additional procedures 
required for other manufacturers to increase production of 
drugs in short supply, or for re-importation of such products.  
 
It may also be necessary to consider specific elements for 
revision of the current definition of medically necessary. For 
example, what would be the qualification standards for a 
"serious disease"? Is there a threshold for its prevalence, 
incidence, and survival period? Would it be feasible for FDA 
to define a list of "serious diseases" for which any disruption 
in treatment would cause detrimental impact to the 
population? A standardized and more precisely defined 
terminology for the indispensable pharmaceutical products 
can facilitate the process of empowering the FDA to regulate 
manufacturers' behavior for the continued production of 
drugs that are deemed medically necessary.   
2. Regulations to halt gray market activities in short supply  
Stronger regulatory actions are needed to control and 
monitor distribution channels for pharmaceutical products. 
Regulatory engagements will focus on two aspects: a national 
pedigree law that restricts the distribution of pharmaceutical 
products to authorized wholesalers (Verified-Accredited 
Wholesale Distributor, VAWD) and with enhanced monitoring 
systems; and standardized pricing from distributors that 
prohibits price gouging, even during drug shortages. A 
coalition from all major stakeholders in the pharmaceutical 
manufacturing-supply chain: manufacturers, authorized 
distributors, pharmacies, healthcare providers and 
consumers. Healthcare providers can take advantage of the 
gray market solicitation and gain insight into potential drug 
shortages, which can lead to optimized planning for the 
allocation of remaining supplies in the practice setting, as 
well as potential exchange of products with other hospitals to 
avoid utilizing gray market vendors. In event of an impending 
shortage, direct ordering from manufacturers should be 
considered, if a situation warrants. Ultimately, FDA is entitled 
to greatly enhanced authorities for its pivotal role in the 
battle against drug shortages. When manufactures know 
their products will soon be in shortage, FDA should be 
informed a minimum of six-month before the shortage 
occurs. To prevent potential purchases from gray market 
vendors during the reporting window, regulations should be 
made to requiring manufactures to stop deliveries to 
distributors and wholesalers after the impending shortage is 
reported to FDA and access to products will be only granted 
only to healthcare practices (e.g. hospitals, clinics, and 
pharmacies).  
 
3. Grant temporary authorization to foreign markets and 
approve pharmaceutical products from Western European 
countries  
Drug purchases over the internet from foreign countries is 
not a new term. Although studies have shown that generic 
drugs in Canada or western Europe were generally more 
expensive than the same products in the US market, without 
even taking shipping cost into consideration, temporary 
regulatory adjustment process to allow larger scale drug 
importation from countries with more established drug 
quality management systems (primarily western European 
countries, Canada, Japan and Australia) can provide relief to 
the current crisis of massive drug shortages. In Europe, the 
majority of drugs are authorized through the European 
Medicines Agency (EMA), a scientific agency that is roughly 
parallel to the US FDA.  A centralized procedure allows 
manufacturers to submit a single application to EMA to 
obtain from the European Commission a centralized (or 
‘Community’) marketing authorization valid in all EU member 
states. A more collaborative relationship between FDA and Idea Paper  POLICY 
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EMA has been cultivated in recent years. Earlier this year, The 
U.S. FDA and the EMA have launched a 3-year pilot program 
that will allow parallel evaluation of new drug marketing 
applications that are submitted to both agencies.
34 By 
imposing regular communication and consultation between 
the two agencies throughout the process, the programs will 
provide further space for FDA and EMA reviewers to share 
full knowledge about the application and harmonize 
regulatory decisions to the greatest extent possible.  
 
While still far away from a unified market, US and Western 
Europe share the commonality in many ways as they pertain 
to drug approval, regulation, quality inspection and 
monitoring. With the amount of foreign produced drugs 
approved in the US increasing steadily over the past decade, 
the FDA's regulatory actions has expanded across Europe, 
Asia and Latin America to ensure the safety of imported 
products.
35 While criticisms were raised against FDA's delayed 
approval of foreign pharmaceutical products to protect 
domestic manufactures and actions have been taken to 
expedite approval of critically needed drugs from foreign 
markets,
36 FDA's approval procedure for foreign drugs is 
heavily based on clinical trial data coming from oversees 
sites. Currently, there are no regulatory procedures to grant 
FDA with sufficient authority to monitor these trials. It is 
encouraged that sponsors of foreign clinical trials voluntarily 
consult with FDA on their trial protocols or submit 
Investigational New Drugs (INDs) to the agency.
37 
 
Conclusion  
The escalating increase in the shortage of drugs has 
compromised patient quality of care and imposed a 
tremendous burden on our health care system. In response 
to the crisis, healthcare and government organizations have 
taken numerous initiatives, aiming to find rapid solutions. 
Nevertheless, the battle against drug shortage is likely to be 
long-term and requires joint efforts from all sectors of the 
health care system, as well as consumers, pharmaceutical 
traders and legal entities. New bills have been proposed to 
prevent or mitigate supply issues, but it will take efforts in 
lobbying for their incorporation into law, and their ultimate 
effect is unclear. Key elements to a successful program for 
managing drug shortages include a good understanding of 
the causes for the shortages, a clear channel for international 
communication and collaboration, and plans with all parties 
involved, and proven strategies for involving the entire health 
care system.  
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Figure 1. Annual New Drug Shortages (2003-2011) 
 
 
Sources: Drug Information Service, University of Utah, 2010; The Washington Post, October 30, 2011. 
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